



25 November 2019

Company Announcements Office
Australian Securities Exchange
Level 4, 20 Bridge Street
Sydney NSW 2000

Changes to Substantial Shareholders and Change of Directors' Interests Notices

Following the issue and subsequent conversion of convertible notes and issue of shares to C2 Ventures Pty Ltd ("C2V") on the terms as approved by shareholders we enclose the following relevant forms on behalf of C2V and related Directors Mr Craig Cooper and Mr Niall Cairns:

- Form 604 – Notice of Change of Interest of Substantial Holder for C2V
- Appendix 3Y – Change of Directors' Interest Notices for Mr Craig Cooper
- Appendix 3Y – Change of Directors' Interest Notices for Mr Niall Cairns

These lodgements reconcile the current holdings of C2V and all share issues to 21 November 2019.

CARDIEX LIMITED

A handwritten signature in blue ink, appearing to read "Jarrod White", written over a faint circular stamp.

JARROD WHITE
CHIEF FINANCIAL OFFICER | COMPANY SECRETARY

For more information please contact:

Chief Financial Officer
Jarrod White
Ph: +61 8296 0000
jwhite@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" (cBP) which is considered essential for the management of hypertension and related cardiovascular disorders. XCEL was developed and is marketed by CardieX's 100% subsidiary, ATCOR.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019, the Company signed an agreement with Mobvoi, Google's partner in China, for the co-development of new wearable technologies and devices based on Mobvoi's smart watch products.

Form 604Corporations Act 2001
Section 671B**Notice of change of interests of substantial holder**To Company Name/Scheme **CardieX Limited**ACN/ARSN **113 252 234****1. Details of substantial holder (1)**Name **C2 Ventures Pty Limited**ACN/ARSN (if applicable) **625 301 528**

There was a change in the interests of the substantial holder on

21/11/2019

The previous notice was given to the company on

07/03/2019

The previous notice was dated

22/05/2019**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
FPO shares	137,616,769	19.78%	158,960,194	22.17%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
20/11/2019	C2 Ventures Pty Limited	Conversion of convertible notes to shares	\$640,303	21,343,425 FPO shares	21,343,425

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
C2 Ventures Pty Limited	C2 Ventures Pty Limited	C2 Ventures Pty Limited	Registered holder of share	158,960,194 FPO shares	158,960,194

--	--	--	--	--	--

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
C2 Ventures Pty Limited	Suite 305, 35 Lime Street, Sydney NSW 2000

Signature

print name **Jarrod Travers White** capacity **Company Secretary**

sign here

date **25/11/2019**

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity CardieX Limited
ABN 81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Craig Cooper
Date of last notice	22/05/2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Shares issued to: 1. C2 Ventures Pty Ltd
Date of change	21 November 2019
No. of securities held prior to change	Direct: NIL Indirect: CooperativeHealth, LLC 3. 36,000,000 Performance Rights C2 Ventures Pty Ltd 1. 137,616,769 FPO 2. 37,500,000 Options at \$0.05 expiring 30 November 2021 4. 861,497 Convertible Notes with face value of \$1 and conversion value of \$0.03 per share
Class	See above

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	<ol style="list-style-type: none"> 21,343,425 FPO NIL NIL NIL
Number disposed	<ol style="list-style-type: none"> NIL NIL NIL 640,303 Notes upon conversion to Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> \$640,303 on conversion of Convertible Notes to Shares NIL NIL NIL
No. of securities held after change	Direct: NIL Indirect: CooperativeHealth, LLC <ol style="list-style-type: none"> 36,000,000 Performance Rights C2 Ventures Pty Ltd <ol style="list-style-type: none"> 158,960,194 FPO 37,500,000 Options at \$0.05 expiring 30 November 2021 221,194 Convertible Notes with face value of \$1 and conversion value of \$0.03 per share
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> 21,343,425 shares issued on conversion of Convertible Note from C2 Ventures Pty Ltd at \$0.03 per share NIL NIL Conversion of 640,303 convertible notes to shares at an issue price of \$0.03 per share

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity CardieX Limited
ABN 81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Niall Charles Edgar Cairns
Date of last notice	22/05/2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Shares issued to: 1. C2 Ventures Pty Ltd
Date of change	21 November 2019
No. of securities held prior to change	Direct: NIL Indirect: C2 Ventures Pty Ltd 1. 137,616,769 FPO 2. 37,500,000 Options at \$0.05 expiring 30 November 2021 4. 861,497 Convertible Notes with face value of \$1 and conversion value of \$0.03 per share Carnethy Evergreen Pty Ltd 3. 3,000,000 FPO
Class	See above

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	<ol style="list-style-type: none"> 21,343,425 FPO NIL NIL NIL
Number disposed	<ol style="list-style-type: none"> NIL NIL NIL 640,303 Notes upon conversion to Shares
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> \$640,303 NIL NIL NIL
No. of securities held after change	<p>Direct: NIL</p> <p>Indirect:</p> <p>C2 Ventures Pty Ltd</p> <ol style="list-style-type: none"> 158,960,194 FPO 37,500,000 Options at \$0.05 expiring 30 November 2021 221,194 Convertible Notes with face value of \$1 and conversion value of \$0.03 per share <p>Carnethy Evergreen Pty Ltd</p> <ol style="list-style-type: none"> 3,000,000 FPO
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> 22,343,425 shares issued on conversion of Convertible Note from C2 Ventures Pty Ltd at \$0.03 per share NIL NIL Conversion of 640,303 convertible notes to shares at an issue price of \$0.03 per share

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.